- Search for Research Summaries, Reviews, and Reports
- EPC Project
Related Products for this Topic
Research Review - Final – Sept. 1, 2009
Comparative Effectiveness of Lipid-Modifying Agents
- Final Report (PDF) 1.1 MB
- Report Appendixes (PDF) 3.8 MB
- Web Version (NLM Site)
- Help with Viewers, Players, and Plug-ins
Archived: This report has been updated.
People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.
This evidence report was commissioned by the Agency for Healthcare Research and Quality (AHRQ) to address the following key questions: Key Question 1. For patients who require intensive lipid-modifying therapy, what are the comparative long-term benefits and rates of serious adverse events of coadministration of different lipid-modifying agents (i.e., a statin plus another lipid-modifying agent) compared with higher dose statin monotherapy? Key Question 2. Do these regimens differ in reaching LDL targets (or other surrogate markers), short-term side effects, tolerability, and/or adherence? Key Question 3. Compared with higher dose statins and to one another, do combination regimens differ in benefits and harms within subgroups of patients?